|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06826 HAOHAI BIOTEC
Nominal 
23.060 +0.780 (+3.501%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 2,446,306 | -8.709% | 2,679,667 | 2,634,910 | 2,103,438 | 1,750,116 |
| Cost of Sales | (734,729) | -9.391% | (810,879) | (781,401) | (656,515) | (490,370) |
| Gross Profit | 1,711,577 | -8.412% | 1,868,788 | 1,853,509 | 1,446,923 | 1,259,746 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (4,620) | -- | 2,229 | 1,973 | (15,516) | 3,182 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 10 | -98.986% | 986 | 456 | 3,505 | 2,193 | |
| Profit / (Loss) before Taxation | 239,246 | -48.676% | 466,145 | 508,260 | 235,726 | 382,649 | |
| Taxation | (30,924) | -65.603% | (89,902) | (95,991) | (45,395) | (35,366) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 42,687 | -3.432% | 44,204 | 3,852 | (9,861) | 4,951 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 251,009 | -40.299% | 420,447 | 416,121 | 180,470 | 352,234 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (57,998) | 3.751% | (55,901) | (70,436) | (80,280) | (93,247) |
| Depreciation & Amortisation | 206,759 | 0.747% | 205,226 | 197,855 | 204,217 | 162,837 |
| Directors' Emoluments | -- | -- | 10,467 | 9,007 | 9,714 | 5,621 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 108.000 | -40.000% | 180.000 | 174.286 | 74.286 | 142.857 |
| DPS (cts) | 100.000 | -- | 100.000 | 71.429 | 28.571 | 50.000 |
| Dividend Payout Ratio (%) | 92.593% | -- | 55.556% | 40.984% | 38.462% | 35.000% |
| Cash flow per share ($) | -- | -- | 2.782 | 2.657 | 1.333 | 1.943 |
| NBV per share ($) | 23.915 | -- | 23.908 | 23.535 | 22.621076 | 23.211219 |
| Remarks: | Real time quote last updated: 24/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 251,009 |
| %Change | -40.299% |
| EPS / (LPS) | RMB 1.080 |
| NBV Per Share (¥) | RMB 23.915 |